FOLD
$14.37
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
Recent News
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside
Why Amicus Therapeutics stands out today Amicus Therapeutics (FOLD) has drawn attention recently as investors weigh its current share price of US$14.37 against the company’s rare disease portfolio, revenue of US$634.21 million, and net loss of US$27.11 million. See our latest analysis for Amicus Therapeutics. At a share price of US$14.37, Amicus Therapeutics has seen a 32.08% 3 month share price return, while its 1 year total shareholder return of 61.46% contrasts with more modest multi year...
Viking Therapeutics Stock Gets RS Rating Upgrade
Viking Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Rice Hall James Loads Up on BIRK With 466,000 Shares Bought
Birkenstock sells premium footwear via global channels, reaching comfort-focused consumers across major international markets.
Rice Hall James Buys QuidelOrtho Stock
QuidelOrtho develops diagnostic technologies for healthcare providers worldwide, spanning labs, clinics, and retail settings.
Rice Hall James Buys Stride Stock
Stride delivers online and blended education solutions for K-12, career, and adult learners through proprietary technology platforms.